Literature DB >> 1752698

Spontaneous monokine release by alveolar macrophages in chronic sarcoidosis.

J Strausz1, D N Männel, S Pfeifer, A Borkowski, R Ferlinz, J Müller-Quernheim.   

Abstract

In pulmonary sarcoidosis an activation of alveolar T lymphocytes and alveolar macrophages (AM) has been demonstrated. There is evidence that in contrast to acute disease a heightened T-cell response cannot be observed in the chronic phase of sarcoidosis. The role of AM in the inflammatory process of chronic sarcoidosis is not yet intensively evaluated. To address this question we measured the release of tumor necrosis factor alpha (TNF alpha) and interleukin-1 (IL-1) by AM of 39 patients with chronic sarcoidosis (duration greater than 4 years; 30 active, 9 inactive diseases) without therapy and correlated the monokine release with parameters of T-cell alveolitis and the course of the disease. The T4/T8 ratio was higher in the active than in the inactive group without reaching statistical significance. TNF alpha as well as IL-1 is spontaneously released by AM of the active group 2,099 +/- 518 pg/ml TNF alpha/10(6) cells/24 h and 8/13 (IL-1+/total) respectively. In the inactive group the AM release 375 +/- 246 pg/ml TNF alpha/10(6) cells/24 h which is in the range of the control and 1 out of 5 patients was IL-1-positive. There was no correlation between the monokine release and any parameter of T-cell alveolitis. These data support the hypothesis that the inflammatory process in chronic sarcoidosis is dominated by the activity of AM and that this activity determines the course of the disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752698     DOI: 10.1159/000235537

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  11 in total

Review 1.  Sarcoidosis--scientific progress and clinical challenges.

Authors:  Edward S Chen; David R Moller
Journal:  Nat Rev Rheumatol       Date:  2011-07-12       Impact factor: 20.543

2.  Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis.

Authors:  I Bäumer; G Zissel; M Schlaak; J Müller-Quernheim
Journal:  Lung       Date:  1997       Impact factor: 2.584

3.  A Novel In Vitro Human Granuloma Model of Sarcoidosis and Latent Tuberculosis Infection.

Authors:  Elliott D Crouser; Peter White; Evelyn Guirado Caceres; Mark W Julian; Audrey C Papp; Landon W Locke; Wolfgang Sadee; Larry S Schlesinger
Journal:  Am J Respir Cell Mol Biol       Date:  2017-10       Impact factor: 6.914

Review 4.  Immunogenetics of Disease-Causing Inflammation in Sarcoidosis.

Authors:  Johan Grunewald; Paolo Spagnolo; Jan Wahlström; Anders Eklund
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

5.  Evaluation of soluble CD 14 and neopterin as serum parameters of the inflammatory activity of pulmonary sarcoidosis.

Authors:  J Homolka; J Lorenz; H D Zuchold; J Müller-Quernheim
Journal:  Clin Investig       Date:  1992-10

6.  Antigen-induced alveolitis: cytokine production in a mouse model.

Authors:  M Denis; D Bisson
Journal:  Inflammation       Date:  1995-04       Impact factor: 4.092

7.  Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis.

Authors:  J Müller-Quernheim; S Pfeifer; K Kienast; G Zissel
Journal:  Lung       Date:  1996       Impact factor: 2.584

8.  Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis.

Authors:  Maria Wikén; Johan Grunewald; Anders Eklund; Jan Wahlström
Journal:  J Clin Immunol       Date:  2008-09-05       Impact factor: 8.317

9.  Increased interleukin 6 production by bronchoalveolar lavage cells in patients with active sarcoidosis.

Authors:  J Homolka; J Müller-Quernheim
Journal:  Lung       Date:  1993       Impact factor: 2.584

10.  Preface.

Authors:  P L Giorgi; N Oggiano; A Kantar; A Corrias
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.